Chemical Structure (Lantus 01)
Chemical structure diagram of insulin glargine showing the A and B chains with amino acid sequence and disulfide bonds.*
Lantus Solostar Injection, Solution
Product Images NDC 50090-4068
20 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Lantus Solostar (NDC 50090-4068). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Lantus 02)
A line graph comparing glucose infusion rates (mg/kg/min) over time (hours) after subcutaneous injection for insulin glargine and NPH insulin in 20 subjects each. The graph shows time on the x-axis up to 30 hours, with glucose infusion rate on the y-axis, peaking higher and earlier for NPH insulin and lower and more sustained for insulin glargine. An end of observation period is marked at around 26 hours.*
Figure (Lantus 03)
An instructional illustration showing a hand holding an opened vial, preparing it for use, likely part of dosing or administration instructions for LANTUS SOLOSTAR insulin glargine injection.*
Figure (Lantus 04)
An instructional illustration showing hands applying or removing a tape or adhesive strip from the top of a vial, likely demonstrating how to access the vial's rubber stopper for injection preparation.*
Figure (Lantus 05)
An instructional line drawing depicting hands preparing a syringe for injection. One hand holds the syringe barrel while the other adjusts the plunger, illustrating the technique to draw or release the solution. The image appears intended to guide users in injecting medication subcutaneously.*
Figure (Lantus 06)
An instructional black-and-white illustration demonstrating how to draw medication from a vial using a syringe. The image shows one hand holding the vial inverted and the other hand pulling back the syringe plunger to draw the solution into the syringe.*
Figure (Lantus 07)
An instructional line drawing showing a hand holding a syringe with an arrow indicating a downward motion, likely demonstrating injection technique or preparation steps for LANTUS SOLOSTAR insulin glargine injection solution 100 units/mL.*
Figure (Lantus 08)
An instructional illustration showing a hand holding an insulin syringe, preparing to inject or draw insulin, with an arrow indicating the direction of movement. The image likely demonstrates technique involving LANTUS SOLOSTAR insulin glargine injection.*
Figure (Lantus 09)
An instructional illustration showing a hand holding a LANTUS SOLOSTAR injection pen, demonstrating the subcutaneous injection technique by injecting the insulin solution into the skin, likely representing patient self-administration guidance.*
Figure (Lantus 10)
An instructional illustration showing the steps for preparing an injection. It depicts a hand holding a syringe and another hand pulling on the plunger, highlighting the technique for drawing medication from a vial or preparing the injection dose.*
Figure (Lantus 11)
An instructional illustration showing components of the LANTUS SOLOSTAR insulin glargine 100 IU/mL injection pen by A-S Medication Solutions. The diagram identifies the pen cap, pen needle parts (outer needle cap, inner needle cap, needle, protective seal), and pen body features including insulin reservoir with label, rubber seal, dose window, dosage selector, and injection button, illustrating the pen's design for subcutaneous injection use.*
Figure (Lantus 12)
An instructional diagram showing the preparation of an injection device by removing a protective cap from the needle end, with hands holding the injector pen labeled for subcutaneous injection.*
Figure (Lantus 13)
An instructional line drawing showing hands interacting with a LANTUS SOLOSTAR injection pen. The illustration features a large red 'X' across it, indicating an action not to perform with the pen. The image emphasizes proper handling of the injection pen prior to use.*
Figure (Lantus 14)
An instructional illustration showing a hand holding an insulin glargine injection pen with a red arrow indicating a twisting or turning motion on the pen's dose selector. The image demonstrates how to adjust the dosage on the pen for subcutaneous injection.*
Figure (Lantus 15)
An instructional diagram illustrating a step in the use or preparation of an injection pen, showing a needle cap to keep and a needle to discard, indicating proper handling of injection components for subcutaneous administration.*
Figure (Lantus 16)
An instructional illustration showing a syringe with a capped needle. A hand is depicted removing the needle cap by pulling it upwards. The needle and cap are highlighted with a red circle and arrow to emphasize the action of uncapping the needle for use.*
Figure (Lantus 17)
An instructional diagram showing a hand adjusting the dose selection knob on a LANTUS SOLOSTAR insulin glargine injection pen. A red arrow indicates the direction to turn the dial to set the insulin dose.*
Figure (Lantus 18)
Illustration showing proper technique for holding an injection syringe. A hand grips the barrel of the syringe with the thumb positioned to push the plunger, and the needle pointing outward, indicated by a red arrow. This demonstrates how to administer a subcutaneous injection.*
Figure (Lantus 19)
An instructional illustration showing a hand holding a LANTUS SOLOSTAR insulin glargine injection pen, with an arrow indicating the pressing direction and a 10-second timer icon, likely demonstrating the correct injection technique or needle pressing duration.*
Label Image (Lbl500904068)
LANTUS SOLOSTAR insulin glargine injection solution label showing the product name, strength of 100 units/mL, dosage form as injection for subcutaneous use, and labeler A-S Medication Solutions. The label indicates each milliliter contains 100 units (3.6378 mg) insulin glargine. Storage instructions specify refrigeration at 36 to 46 degrees Fahrenheit and not freezing. The package contains five 3 mL prefilled pens.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
